176 related articles for article (PubMed ID: 23145140)
41. Peptide-mediated liposomal Doxorubicin enhances drug delivery efficiency and therapeutic efficacy in animal models.
Chang DK; Li PC; Lu RM; Jane WN; Wu HC
PLoS One; 2013; 8(12):e83239. PubMed ID: 24386166
[TBL] [Abstract][Full Text] [Related]
42. Heparan sulfate targeting strategy for enhancing liposomal drug accumulation and facilitating deep distribution in tumors.
Kuo PH; Teng YH; Cin AL; Han W; Huang PW; Wang LH; Chou YT; Yang JL; Tseng YL; Kao M; Chang MD
Drug Deliv; 2020 Dec; 27(1):542-555. PubMed ID: 32241176
[TBL] [Abstract][Full Text] [Related]
43. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
J Liposome Res; 2016 Dec; 26(4):276-87. PubMed ID: 26784587
[TBL] [Abstract][Full Text] [Related]
44. Importance of the fatty acid chain length on in vitro and in vivo anticancer activity of fattigation-platform albumin nanoparticles in human colorectal cancer xenograft mice model.
Park C; Baek N; Loebenberg R; Lee BJ
J Control Release; 2020 Aug; 324():55-68. PubMed ID: 32380202
[TBL] [Abstract][Full Text] [Related]
45. Peptide-modified liposomes for selective targeting of bombesin receptors overexpressed by cancer cells: a potential theranostic agent.
Accardo A; Salsano G; Morisco A; Aurilio M; Parisi A; Maione F; Cicala C; Tesauro D; Aloj L; De Rosa G; Morelli G
Int J Nanomedicine; 2012; 7():2007-17. PubMed ID: 22619538
[TBL] [Abstract][Full Text] [Related]
46. Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells.
Mamot C; Ritschard R; Wicki A; Küng W; Schuller J; Herrmann R; Rochlitz C
J Drug Target; 2012 Jun; 20(5):422-32. PubMed ID: 22519893
[TBL] [Abstract][Full Text] [Related]
47. Lipoic acid-derived cross-linked liposomes for reduction-responsive delivery of anticancer drug.
Ling L; Ismail M; Du Y; Yao C; Li X
Int J Pharm; 2019 Apr; 560():246-260. PubMed ID: 30769133
[TBL] [Abstract][Full Text] [Related]
48. GE11-Directed Functional Polymersomal Doxorubicin as an Advanced Alternative to Clinical Liposomal Formulation for Ovarian Cancer Treatment.
Zou Y; Xia Y; Meng F; Zhang J; Zhong Z
Mol Pharm; 2018 Sep; 15(9):3664-3671. PubMed ID: 29570299
[TBL] [Abstract][Full Text] [Related]
49. Enhancement of antitumor effect of doxorubicin by its complexation with gamma-cyclodextrin in pegylated liposomes.
Arima H; Hagiwara Y; Hirayama F; Uekama K
J Drug Target; 2006 May; 14(4):225-32. PubMed ID: 16777681
[TBL] [Abstract][Full Text] [Related]
50. Enhanced in vivo antitumor efficacy of doxorubicin encapsulated within laponite nanodisks.
Li K; Wang S; Wen S; Tang Y; Li J; Shi X; Zhao Q
ACS Appl Mater Interfaces; 2014 Aug; 6(15):12328-34. PubMed ID: 25000274
[TBL] [Abstract][Full Text] [Related]
51. Robust, active tumor-targeting and fast bioresponsive anticancer nanotherapeutics based on natural endogenous materials.
Sun B; Deng C; Meng F; Zhang J; Zhong Z
Acta Biomater; 2016 Nov; 45():223-233. PubMed ID: 27576338
[TBL] [Abstract][Full Text] [Related]
52. Synthesis of doxorubicin α-linolenic acid conjugate and evaluation of its antitumor activity.
Liang CH; Ye WL; Zhu CL; Na R; Cheng Y; Cui H; Liu DZ; Yang ZF; Zhou SY
Mol Pharm; 2014 May; 11(5):1378-90. PubMed ID: 24720787
[TBL] [Abstract][Full Text] [Related]
53. Increasing the antitumor efficacy of doxorubicin liposomes with coupling an anti-EGFR affibody in EGFR-expressing tumor models.
Jia D; Yang Y; Yuan F; Fan Q; Wang F; Huang Y; Song H; Hu P; Wang R; Li G; Liu R; Li J
Int J Pharm; 2020 Aug; 586():119541. PubMed ID: 32544521
[TBL] [Abstract][Full Text] [Related]
54. cRGD-decorated biodegradable polytyrosine nanoparticles for robust encapsulation and targeted delivery of doxorubicin to colorectal cancer in vivo.
Gu X; Wei Y; Fan Q; Sun H; Cheng R; Zhong Z; Deng C
J Control Release; 2019 May; 301():110-118. PubMed ID: 30898610
[TBL] [Abstract][Full Text] [Related]
55. The antitumor activity of tumor-homing peptide-modified thermosensitive liposomes containing doxorubicin on MCF-7/ADR: in vitro and in vivo.
Wang C; Wang X; Zhong T; Zhao Y; Zhang WQ; Ren W; Huang D; Zhang S; Guo Y; Yao X; Tang YQ; Zhang X; Zhang Q
Int J Nanomedicine; 2015; 10():2229-48. PubMed ID: 25834435
[TBL] [Abstract][Full Text] [Related]
56. Chitooligosaccharides Modified Reduction-Sensitive Liposomes: Enhanced Cytoplasmic Drug Delivery and Osteosarcomas-Tumor Inhibition in Animal Models.
Yin X; Chi Y; Guo C; Feng S; Liu J; Sun K; Wu Z
Pharm Res; 2017 Oct; 34(10):2172-2184. PubMed ID: 28726003
[TBL] [Abstract][Full Text] [Related]
57. Dual-effect liposomes encapsulated with doxorubicin and chlorin e6 augment the therapeutic effect of tumor treatment.
Peng PC; Hong RL; Tsai YJ; Li PT; Tsai T; Chen CT
Lasers Surg Med; 2015 Jan; 47(1):77-87. PubMed ID: 25559348
[TBL] [Abstract][Full Text] [Related]
58. Selective Activation of Anticancer Chemotherapy by Cancer-Associated Fibroblasts in the Tumor Microenvironment.
Kim MG; Shon Y; Kim J; Oh YK
J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27615014
[TBL] [Abstract][Full Text] [Related]
59. The structure of polymer carriers controls the efficacy of the experimental combination treatment of tumors with HPMA copolymer conjugates carrying doxorubicin and docetaxel.
Šírová M; Strohalm J; Chytil P; Lidický O; Tomala J; Říhová B; Etrych T
J Control Release; 2017 Jan; 246():1-11. PubMed ID: 27940304
[TBL] [Abstract][Full Text] [Related]
60. Selenium-functionalized liposomes for systemic delivery of doxorubicin with enhanced pharmacokinetics and anticancer effect.
Xie Q; Deng W; Yuan X; Wang H; Ma Z; Wu B; Zhang X
Eur J Pharm Biopharm; 2018 Jan; 122():87-95. PubMed ID: 29032193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
